VTYX - Why Shares of Ventyx Biosciences Rose Monday
2023-07-03 14:09:59 ET
On Monday, shares of Ventyx Biosciences (NASDAQ: VTYX) closed 22.87% higher than they did last week. The clinical-stage biotech hit more than $40 a share for the first time since March 10.
Ventyx focuses on therapies to treat inflammatory diseases and autoimmune disorders. The company has four programs in its pipeline, including two in phase 2 trials:
Investors looking for clues about how the programs are going got excited Monday even though the company reported through its Securities and Exchange Commission filings that several insiders were unloading company stock.
For further details see:
Why Shares of Ventyx Biosciences Rose Monday